Launching in EU – Q&A 10

How can we leverage early access programs and real-world evidence (RWE) to support our European launch?

What’s Inside the Q&A:

• Early Access Advantage – Uncover how early patient programs can bridge regulatory gaps and build support ahead of launch.
• Country-by-Country Insights – See how major European markets approach early access – and what that means for your rollout plan.
• Power of Real-World Data – Learn why evidence from real use can sway payers, shape HTA outcomes, and sustain long-term value.
• Integrated Launch Strategy – Find out how combining early access with data generation can accelerate uptake and reinforce credibility.